Literature DB >> 9021049

Assessment of pain in herpes zoster: lessons learned from antiviral trials.

R H Dworkin1, D Carrington, A Cunningham, R G Kost, M J Levin, M W McKendrick, M N Oxman, B Rentier, K E Schmader, G Tappeiner, S W Wassilew, R J Whitley.   

Abstract

Pain typically accompanies acute herpes zoster and, in a proportion of patients, it persists well beyond rash healing. Pain must therefore be analyzed in trials of antiviral agents in herpes zoster, but different methods have been used to analyze pain in recent published trials. These reports are reviewed and their methodological strengths and weaknesses examined. Based on this review, recommendations for the design and analysis of future trials of antiviral agents in herpes zoster are proposed. The principal recommendation is that antiviral efficacy should be evaluated both by distinguishing post-herpetic neuralgia from acute pain and by considering pain as a continuum. The primary endpoint should address both the prevalence and duration of post-herpetic neuralgia and should be examined in those patients who have post-herpetic neuralgia. Adopting the proposed recommendations in design and analysis of future trials should facilitate comparison across trials of the efficacy of antiviral agents in the treatment of herpes zoster.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021049     DOI: 10.1016/s0166-3542(96)01007-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

1.  The management of post-herpetic neuralgia.

Authors:  A L Cunningham; R H Dworkin
Journal:  BMJ       Date:  2000-09-30

Review 2.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

3.  Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up.

Authors:  S Helgason; G Petursson; S Gudmundsson; J A Sigurdsson
Journal:  BMJ       Date:  2000-09-30

Review 4.  Tolerability of treatments for postherpetic neuralgia.

Authors:  Mark W Douglas; Robert W Johnson; Anthony L Cunningham
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  [Varicella-zoster virus infections].

Authors:  H M Lilie; S W Wassilew
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

6.  Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

Authors:  Ronald R White; Greg Lenhart; Puneet K Singhal; Ralph P Insinga; Robbin F Itzler; James M Pellissier; Arthur W Segraves
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 7.  The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster.

Authors:  H Martina Lilie; Sawko Wassilew
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy.

Authors:  Giustino Parruti; Monica Tontodonati; Cristina Rebuzzi; Ennio Polilli; Federica Sozio; Augusta Consorte; Adriana Agostinone; Francesco Di Masi; Gabriele Congedo; Domenico D'Antonio; Carla Granchelli; Claudio D'Amario; Carlo Carunchio; Lucio Pippa; Lamberto Manzoli; Antonio Volpi
Journal:  BMC Med       Date:  2010-10-11       Impact factor: 8.775

9.  The PINE study: rationale and design of a randomised comparison of epidural injection of local anaesthetics and steroids versus care-as-usual to prevent postherpetic neuralgia in the elderly [ISRCTN32866390].

Authors:  Wim Opstelten; Albert JM Van Wijck; Gerrit A Van Essen; Erik Buskens; Annette AA Bak; Cornelis J Kalkman; Theo JM Verheij; Karel GM Moons
Journal:  BMC Anesthesiol       Date:  2004-01-26       Impact factor: 2.217

Review 10.  Systematic review of incidence and complications of herpes zoster: towards a global perspective.

Authors:  Kosuke Kawai; Berhanu G Gebremeskel; Camilo J Acosta
Journal:  BMJ Open       Date:  2014-06-10       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.